107 related articles for article (PubMed ID: 23964487)
1. [Excellence in continuous research. MMW medication award for sitagliptin].
Heinzl S
MMW Fortschr Med; 2013 Jul; 155(13):12. PubMed ID: 23964487
[No Abstract] [Full Text] [Related]
2. Sitagliptin: a viewpoint by Itamar Raz.
Raz I
Drugs; 2007; 67(4):598-9. PubMed ID: 17352518
[No Abstract] [Full Text] [Related]
3. Sitagliptin: results from clinical practice.
Maffioli P; Derosa G
Curr Med Res Opin; 2013 Nov; 29(11):1483-5. PubMed ID: 23971498
[No Abstract] [Full Text] [Related]
4. Sitagliptin: a viewpoint by Mark S. Kipnes.
Kipnes MS
Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
[No Abstract] [Full Text] [Related]
5. First-in-class diabetes drug approved.
Traynor K
Am J Health Syst Pharm; 2006 Dec; 63(23):2284. PubMed ID: 17105996
[No Abstract] [Full Text] [Related]
6. A diabetes drug, sitagliptin, also has a potential to prevent diabetes.
Exp Biol Med (Maywood); 2011 Mar; 236(3):xiv. PubMed ID: 21544950
[No Abstract] [Full Text] [Related]
7. An Excellence Award for the Journal of Gastrointestinal and Liver Diseases.
Acalovschi M
J Gastrointestin Liver Dis; 2015 Dec; 24(4):409. PubMed ID: 26697563
[No Abstract] [Full Text] [Related]
8. Eberhard Denk wins ABC Best Paper Award.
Dyllick CE
Anal Bioanal Chem; 2007 Jun; 388(3):505-6. PubMed ID: 17437088
[No Abstract] [Full Text] [Related]
9. Choosing a blood-glucose-lowering agent after metformin.
Diamant M
Lancet; 2012 Jun; 379(9833):2220-1. PubMed ID: 22683135
[No Abstract] [Full Text] [Related]
10. [Treatment with new preparations against type 2 diabetes not sufficiently documented].
Karlsson EA; Palmér M; Malmström R
Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713
[No Abstract] [Full Text] [Related]
11. A case of drug-induced hepatic injury associated with sitagliptin.
Toyoda-Akui M; Yokomori H; Kaneko F; Shimizu Y; Takeuchi H; Tahara K; Motoori T; Ohbu M; Oda M; Hibi T
Intern Med; 2011; 50(9):1015-20. PubMed ID: 21532224
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of glibenclamide and sitagliptin therapy in adult patients with KCNJ11 permanent diabetes.
Sastre J; Luque A; del Val F; Aragonés A; López J
Diabetes Care; 2014; 37(3):e55-6. PubMed ID: 24558086
[No Abstract] [Full Text] [Related]
13. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
[TBL] [Abstract][Full Text] [Related]
14. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
Ando K; Nishimura R; Seo C; Tsujino D; Sakamoto M; Utsunomiya K
Expert Opin Pharmacother; 2014 Dec; 15(17):2479-85. PubMed ID: 25327311
[TBL] [Abstract][Full Text] [Related]
15. Research paper of the year award 2013.
Groves T
BMJ; 2013 Apr; 346():f2512. PubMed ID: 23616033
[No Abstract] [Full Text] [Related]
16. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
Ogawa S; Ishiki M; Nako K; Okamura M; Senda M; Mori T; Ito S
Tohoku J Exp Med; 2011 Feb; 223(2):133-5. PubMed ID: 21304217
[TBL] [Abstract][Full Text] [Related]
17. [Award for the Brazilian clinical research].
Bernardo WM
Rev Assoc Med Bras (1992); 2006; 52(3):125. PubMed ID: 16847510
[No Abstract] [Full Text] [Related]
18. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
Pham DQ; Nogid A; Plakogiannis R
Am J Health Syst Pharm; 2008 Mar; 65(6):521-31. PubMed ID: 18319497
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
